禾元生物
(688765)
| 流通市值：0.00万 | | | 总市值：0.00万 |
| 流通股本：0.00万 | | | 总股本：0.00万 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 132,369,158.98 | - | 160,402,334.66 | 162,751,993.06 |
| 应收票据及应收账款 | 6,359,472.06 | - | 144,362 | 165,129 |
| 应收账款 | 6,359,472.06 | - | 144,362 | 165,129 |
| 预付款项 | 5,038,501.42 | - | 5,039,473.64 | 3,571,246.14 |
| 其他应收款合计 | 978,559.55 | - | 349,054.91 | 342,410.84 |
| 存货 | 80,629,178.22 | - | 50,018,931.96 | 37,328,613.74 |
| 其他流动资产 | 36,200,418.59 | - | 21,388,303.35 | 9,270,413.37 |
| 流动资产平衡项目 | 0 | - | 0 | 0 |
| 流动资产合计 | 261,575,288.82 | - | 237,342,460.52 | 213,429,806.15 |
| 非流动资产: | | | | |
| 固定资产 | 572,143,470.48 | - | 574,495,439.15 | 574,912,089.13 |
| 在建工程 | 245,219,781.91 | - | 133,754,960.52 | 14,844,529.78 |
| 使用权资产 | 23,839,755.53 | - | 25,169,282.43 | 26,811,806.17 |
| 无形资产 | 85,720,129.01 | - | 87,392,440.95 | 89,138,927.97 |
| 长期待摊费用 | 3,198,367.07 | - | 3,558,148.35 | 3,071,066.67 |
| 其他非流动资产 | 125,563,614.03 | - | 99,144.04 | 6,786,078.16 |
| 非流动资产平衡项目 | 0 | - | 0 | 0 |
| 非流动资产合计 | 1,055,685,118.03 | - | 824,469,415.44 | 715,564,497.88 |
| 资产平衡项目 | 0 | - | 0 | 0 |
| 资产总计 | 1,317,260,406.85 | 1,214,016,300 | 1,061,811,875.96 | 928,994,304.03 |
| 流动负债: | | | | |
| 短期借款 | 15,010,500 | - | 10,007,777.78 | - |
| 应付票据及应付账款 | 199,266,076.53 | - | 175,904,216.94 | 92,492,953.22 |
| 应付账款 | 199,266,076.53 | - | 175,904,216.94 | 92,492,953.22 |
| 合同负债 | 2,400,144.25 | - | 2,449,142.88 | 1,674,106.84 |
| 应付职工薪酬 | 4,094,333.39 | - | 8,464,726.23 | 4,445,024.45 |
| 应交税费 | 881,319.92 | - | 596,544.12 | 745,885.93 |
| 其他应付款合计 | 23,042,944.52 | - | 25,400,112.22 | 811,413.43 |
| 一年内到期的非流动负债 | 28,015,980.71 | - | 9,632,389.86 | 6,266,852.98 |
| 其他流动负债 | 82,150.79 | - | 212,094.18 | 110,939.39 |
| 流动负债平衡项目 | 0 | - | 0 | 0 |
| 流动负债合计 | 272,793,450.11 | - | 232,667,004.21 | 106,547,176.24 |
| 非流动负债: | | | | |
| 长期借款 | 470,793,933.41 | - | 183,995,895.56 | 113,280,054.67 |
| 租赁负债 | 19,469,344.45 | - | 19,293,248.28 | 22,021,119.29 |
| 预计负债 | 1,485,066.89 | - | 1,485,066.89 | 1,485,066.89 |
| 递延收益 | 21,811,475.48 | - | 23,022,993.12 | 21,180,736.48 |
| 非流动负债平衡项目 | 0 | - | 0 | 0 |
| 非流动负债合计 | 513,559,820.23 | - | 227,797,203.85 | 157,966,977.33 |
| 负债平衡项目 | 0 | - | 0 | 0 |
| 负债合计 | 786,353,270.34 | 655,301,000 | 460,464,208.06 | 264,514,153.57 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 268,048,646 | - | 268,048,646 | 268,048,646 |
| 资本公积 | 1,195,847,199.92 | - | 1,184,659,915.47 | 1,175,016,316.94 |
| 未分配利润 | -932,988,709.41 | - | -851,360,893.57 | -778,584,812.48 |
| 归属于母公司股东权益平衡项目 | 0 | - | 0 | 0 |
| 归属于母公司股东权益合计 | 530,907,136.51 | 558,715,200 | 601,347,667.9 | 664,480,150.46 |
| 股东权益平衡项目 | 0 | - | 0 | 0 |
| 股东权益合计 | 530,907,136.51 | - | 601,347,667.9 | 664,480,150.46 |
| 负债和股东权益合计 | 1,317,260,406.85 | - | 1,061,811,875.96 | 928,994,304.03 |
| 公告日期 | 2025-09-23 | 2025-06-24 | 2025-03-31 | 2024-12-31 |
| 审计意见(境内) | 标准无保留意见 | | 标准无保留意见 | 标准无保留意见 |